Prot#: ISIS 766720-CS2: A Double Blind, Placebo-Controlled, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of ISIS 766720 (IONIS GHR-LRX, an Antisense Inhibitor of the Growth Hormone Receptor) Administered Once Every 28 Days for 16 Weeks i

Project: Research project

Project Details

Effective start/end date4/3/194/3/22


  • Medpace Clinical Research LLC (ISIS 766720-CS2 // ISIS 766720-CS2)
  • Ionis Pharmaceuticals, Inc. (ISIS 766720-CS2 // ISIS 766720-CS2)